The company is focused on the clinical development and commercial exploitation through partnering of its highly innovative anti-infective portfolio and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.

In 2023, Destiny entered a collaboration and license agreement with Sebela Pharmaceuticals giving it exclusive development and commercialisation rights to NTCD-M3 in North America.

Destiny also signed a deal with China Medical Systems in 2017 giving it rights to the Destiny programmes for Greater China and related territories.

Please contact us to start a discussion.